pfs48/45
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 2022 (NCT05400746)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Plasmodium falciparumImmunity, active
Plasmodium falciparum immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06549257 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2024 | European and Developing Countries Clinical Trials Partnership (EDCTP), University of Oxford |
| NCT05400746 | Early Phase 1 (Phase 1) | Nov 2, 2022 | University of Oxford |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Oxford | Academic/Hospital | 2 | 2 | 2 | 2022 |
| European and Developing Countries Clinical Trials Partnership (EDCTP) | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1